~~<i id='A300D1DF9B'><strike id='A300D1DF9B'><tt id='A300D1DF9B'><pre id='A300D1DF9B'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：entertainment 2025-09-27 23:18:33 Page View：699

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： CommonSpirit Health keeps growing, even as it loses money
Next article： Heart attack and stroke risk calculators need revising

focus

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Senators: Long

Sen.EdMarkeyofMassachusetts(above)andSen.JoeManchinofWestVirginiahadwordsofwarningforFDACommissioner

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

My chronic pain journey would have been easier knowing 5 things % STAT

AdobeI’vebeenlivingwithchronicpainformorethanadecade.Itbeganin2009withnervedamageafteremergencygroin

WSS

focus

focus

explore

focus

My chronic pain journey would have been easier knowing 5 things % STAT